JP2789134B2 - 糖尿病の合併症を制御する置換ピリミジン類 - Google Patents

糖尿病の合併症を制御する置換ピリミジン類

Info

Publication number
JP2789134B2
JP2789134B2 JP6509004A JP50900494A JP2789134B2 JP 2789134 B2 JP2789134 B2 JP 2789134B2 JP 6509004 A JP6509004 A JP 6509004A JP 50900494 A JP50900494 A JP 50900494A JP 2789134 B2 JP2789134 B2 JP 2789134B2
Authority
JP
Japan
Prior art keywords
alkyl
general formula
compound
hydrogen
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP6509004A
Other languages
English (en)
Japanese (ja)
Other versions
JPH07507072A (ja
Inventor
エル． マイレリ，バナヴァラ
ジェイ． オーツ，ピーター
ダブリュ． シーゲル，トッド
ジェイ． ゼンブロウスキ，ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of JPH07507072A publication Critical patent/JPH07507072A/ja
Application granted granted Critical
Publication of JP2789134B2 publication Critical patent/JP2789134B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP6509004A 1992-09-28 1993-07-12 糖尿病の合併症を制御する置換ピリミジン類 Expired - Fee Related JP2789134B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95222292A 1992-09-28 1992-09-28
US952,222 1992-09-28

Publications (2)

Publication Number Publication Date
JPH07507072A JPH07507072A (ja) 1995-08-03
JP2789134B2 true JP2789134B2 (ja) 1998-08-20

Family

ID=25492671

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6509004A Expired - Fee Related JP2789134B2 (ja) 1992-09-28 1993-07-12 糖尿病の合併症を制御する置換ピリミジン類

Country Status (15)

Country Link
US (2) US5728704A (enFirst)
EP (1) EP0662962A1 (enFirst)
JP (1) JP2789134B2 (enFirst)
KR (1) KR950703539A (enFirst)
AU (1) AU683620B2 (enFirst)
CA (1) CA2145640C (enFirst)
FI (1) FI934224L (enFirst)
HU (1) HU220669B1 (enFirst)
IL (1) IL107085A (enFirst)
MY (1) MY115288A (enFirst)
NO (1) NO306598B1 (enFirst)
NZ (1) NZ254550A (enFirst)
TW (1) TW284759B (enFirst)
WO (1) WO1994007867A1 (enFirst)
ZA (1) ZA937142B (enFirst)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2145640C (en) * 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications
ES2114662T3 (es) * 1993-08-26 1998-06-01 Ono Pharmaceutical Co Derivados de la 4-aminopirimidina.
GB9325217D0 (en) * 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
ATE216226T1 (de) * 1996-02-29 2002-05-15 Pfizer Verwendung von sorbitol-dehydrogenase-inhibitoren zum reduzieren von ischämie-assozierten gewebeschäden
DK0970095T3 (da) 1997-03-07 2004-03-08 Metabasis Therapeutics Inc Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6054587A (en) * 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
EP1402895A1 (en) * 1997-03-07 2004-03-31 Metabasis Therapeutics, Inc. Benzimidazole inhibitors of fructose 1,6-biphosphatase
DE19710435A1 (de) * 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
EA002885B1 (ru) * 1997-04-15 2002-10-31 Ссир Средства растительного происхождения для подавления аппетита
IL124236A (en) * 1997-05-05 2003-01-12 Pfizer Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor
AU2003242500B2 (en) * 1998-09-09 2006-11-02 Metabasis Therapeutics, Inc. Novel Heteroaromatic Inhibitors of Fructose 1,6-bisphosphatase
CN1900087A (zh) * 1998-09-09 2007-01-24 症变治疗公司 新的果糖1,6－二磷酸酶的杂芳族抑制剂
CN1215076C (zh) * 1998-09-09 2005-08-17 症变治疗公司 新的果糖1,6－二磷酸酶的杂芳族抑制剂
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
ES2215570T3 (es) * 1999-04-01 2004-10-16 Pfizer Products Inc. Compuestos para tratar y prevenir complicaciones diabeticas.
AU768720B2 (en) * 1999-04-01 2004-01-08 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
US6380200B1 (en) * 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
SK8892002A3 (en) * 1999-12-22 2003-04-01 Metabasis Therapeutics Inc Novel bisamidate phosphonate prodrugs, process for their preparation and use thereof
CN1516705A (zh) * 2000-03-08 2004-07-28 ֢�����ƹ�˾ 新的芳基果糖-1,6-二磷酸酶抑制剂
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
DK1335906T3 (da) * 2000-11-10 2007-02-05 Hoffmann La Roche Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander
ES2230378T3 (es) * 2000-11-30 2005-05-01 Pfizer Products Inc. Combinacion de agonistas de gaba e inhibidores de sorbitol deshidrogenasa.
AP2001002359A0 (en) * 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
US6555573B2 (en) * 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
US7081470B2 (en) 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US20040127502A1 (en) * 2001-01-31 2004-07-01 Synaptic Pharmaceutical Corporation Use of GAL3 antagonist for treatment of depression
EP1247809A3 (en) 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
AU2002341257A1 (en) * 2001-10-15 2003-04-28 Pfizer Products Inc. Three dimensional crystal structure of human sorbitol dehydrogenase and uses thereof
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
BR0306988A (pt) * 2002-01-18 2004-11-23 Pharmacia Corp Piridazinonas substituìdas como inibidores de p38
EP1483247B1 (en) 2002-03-13 2009-06-24 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
WO2004000318A2 (en) * 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003245669A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
US7083813B2 (en) * 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
AU2005244450B2 (en) * 2004-05-19 2010-08-19 Solvay Pharmaceuticals Gmbh Medicaments containing N-sulfamoyl-N'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
US20050261292A1 (en) * 2004-05-19 2005-11-24 Solvay Pharmaceuticals Gmbh Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
RU2007102288A (ru) * 2004-08-18 2008-09-27 Мебабазис Терапеутикс, Инк. (Us) Новые тиазольные ингибиторы фруктозо-1,6-бисфосфатазы
EP1796673A2 (en) * 2004-09-23 2007-06-20 Reddy US Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
BRPI0518300A2 (pt) * 2004-11-23 2008-11-11 Warner Lambert Co derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
BRPI0519013A2 (pt) * 2004-12-13 2009-11-03 Lilly Co Eli composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7863446B2 (en) * 2006-01-19 2011-01-04 Orchid Research Laboratories Limited Heterocycles
CN101360717B (zh) * 2006-01-19 2014-04-16 幽兰化学医药有限公司 包含嘧啶环的化合物
US8158667B2 (en) * 2006-08-21 2012-04-17 Kador Peter F Topical treatment of cataracts in dogs
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
NZ580266A (en) 2007-04-27 2012-03-30 Purdue Pharma Lp Trpv1 inhibitors / antagonists and uses thereof
WO2009095773A2 (en) 2008-02-01 2009-08-06 Orchid Research Laboratories Limited Novel heterocycles
EP2571860A1 (en) 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl benzoylamides
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
EP2680874A2 (en) 2011-03-04 2014-01-08 Pfizer Inc Edn3-like peptides and uses thereof
LT2723732T (lt) 2011-06-22 2017-02-27 Purdue Pharma Lp Trpv1 antagonistai, įskaitant dihidroksi pakaitą, ir jų panaudojimas
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
SI3352754T1 (sl) 2016-06-21 2021-03-31 The Trustees Of Columbia University In The City Of New York Zaviralci aldozne reduktaze in postopki njihove uporabe
EP3658142B1 (en) 2017-07-28 2024-04-17 Applied Therapeutics, Inc. Compositions and methods for treating galactosemia
CN108101883B (zh) * 2018-01-31 2018-11-13 佳木斯大学附属第一医院 一种用于防治糖尿病视网膜病变的药物及其制备方法
AU2020209215B2 (en) 2019-01-18 2023-02-02 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CA3132136A1 (en) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibitors of aldose reductase
CA3136100A1 (en) 2019-05-07 2020-11-12 Stephan L. ZUCHNER Treatment and detection of inherited neuropathies and associated disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1063014A (fr) * 1950-06-14 1954-04-29 Wellcome Found Dérivés de pyrimidine et leur préparation
GB959699A (en) * 1961-06-09 1964-06-03 May & Baker Ltd New pyrimidine derivatives
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
FR2489141A1 (fr) * 1980-09-03 1982-03-05 Sevifra Appareil chirurgical pour la decoupe precise de la cornee
DOP1981004033A (es) * 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
CA1176269A (en) * 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
US5066659A (en) * 1984-10-30 1991-11-19 Pfizer Inc. Spiro-heteroazalones for treatment of diabetic complications
US5102908A (en) * 1985-03-15 1992-04-07 Michael Albeck Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
JPH0637473B2 (ja) * 1985-10-11 1994-05-18 三共株式会社 ラクタム化合物
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4835410A (en) * 1988-02-26 1989-05-30 Black & Decker Inc. Dual-mode corded/cordless system for power-operated devices
GB8810203D0 (en) * 1988-04-29 1988-06-02 Ici Plc Heterocyclic compounds
GB8902405D0 (en) * 1989-02-03 1989-03-22 Ici Plc Heterocyclic compounds
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US5039672A (en) * 1990-04-05 1991-08-13 Pfizer Inc. Heterocyclic compounds as aldose reductase inhibitors
US5098904A (en) * 1990-06-27 1992-03-24 Bristol-Myers Squibb Company Cerebral function enhancing pyrimidinyl derivatives
GB9016984D0 (en) * 1990-08-02 1990-09-19 Ici Plc Aniline derivatives
DE4025387A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als reagenzien
CA2090027A1 (en) * 1990-08-31 1992-03-01 Shoichi Chokai Pyrimidine derivatives and drugs
CA2145640C (en) * 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications

Also Published As

Publication number Publication date
FI934224A0 (fi) 1993-09-27
IL107085A0 (en) 1993-12-28
FI934224A7 (fi) 1994-03-29
AU683620B2 (en) 1997-11-20
CA2145640A1 (en) 1994-04-14
FI934224L (fi) 1994-03-29
US5866578A (en) 1999-02-02
ZA937142B (en) 1995-03-23
CA2145640C (en) 2001-01-30
HU9302734D0 (en) 1993-12-28
HUT65531A (en) 1994-06-28
TW284759B (enFirst) 1996-09-01
EP0662962A1 (en) 1995-07-19
NO306598B1 (no) 1999-11-29
HU220669B1 (hu) 2002-04-29
US5728704A (en) 1998-03-17
KR950703539A (ko) 1995-09-20
NO951155L (no) 1995-05-26
WO1994007867A1 (en) 1994-04-14
NZ254550A (en) 1997-08-22
IL107085A (en) 2001-01-11
MY115288A (en) 2003-05-31
JPH07507072A (ja) 1995-08-03
NO951155D0 (no) 1995-03-27
AU4669793A (en) 1994-04-26

Similar Documents

Publication Publication Date Title
JP2789134B2 (ja) 糖尿病の合併症を制御する置換ピリミジン類
EP1041068B1 (en) Compounds for treating and preventing diabetic complications
US5594015A (en) Thiazolidine derivatives for the treatment of psoriasis
WO2020146636A1 (en) Compounds and methods for treating or preventing heart failure
US6110951A (en) Thiazolidine derivatives for the treatment of hypertension
JPH09505055A (ja) サイトカイン媒介疾患治療用オキサゾール
JPH10500413A (ja) 新規化合物
JPH06199811A (ja) ジアザ化合物
TWI630204B (zh) 呼吸器官疾病用藥
JP2001518507A (ja) 新規シクロアルケニル置換化合物
JPS5940388B2 (ja) ヒダントイン誘導体治療剤
KR20020073176A (ko) 불안증 개선 방법
KR100478798B1 (ko) 4-헤테로사이클릴설폰아미딜-6-메톡시-5-(2-메톡시-페녹시)-2-피리딜-피리미딘 유도체, 그의 제조 방법 및 엔도텔린수용체 길항제로서의 그의 용도
JPH10511978A (ja) アルツハイマー病の治療用薬剤
US20030040531A1 (en) Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist
US20090298745A1 (en) Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
EP0469837B1 (en) Use of a compound in the manufactur of a medicament for lowering of blood uric acid levels
HUT67836A (en) Pyridazinone acetic acids having aldose reductase inhibitory activity, pharmaceutical compositions containing them and process for preparation of them
AU714038B2 (en) Method of reducing tissue damage associated with ischemia
JPH06211814A (ja) （チオ）ウレア誘導体
EP0517877A1 (en) Novel 3(2h)-pyridazinones, pharmaceutical compositions containing them and process for preparing same
JPH07267859A (ja) 心筋再灌流損傷及び心筋気絶の治療剤
MXPA00003243A (en) Compounds for treating and preventing diabetic complications
AU2959999A (en) Preventives/remedies for urinary disorder
WO1992015296A1 (en) Remedy for renal diseases

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees